Navigation Links
Leukemia Drug Breakthrough Study In New England Journal Of Medicine

Alan List, M.D., leader of the Hematologic Malignancies Program at the H. Lee Moffitt Cancer Center & Research Institute, recently conducted a phase I/II trial of the experimental drug Revlimid showing promise as an innovative way to treat patients with myelodysplastic syndrome (MDS), a form of pre-leukemia. Given in pill form, Revlimid simultaneously blocks the growth of new blood vessels that nourish tumors (anti-angiogenesis) and stimulates the immune system to fight cancer cells. The study is reported in the Feb.10 issue of the New England Journal of Medicine.

Nearly 90 percent of MDS patients are anemic and require regular transfusions of red cells. In this study, 91 percent of the MDS patients with a chromosome abnormality named 5q minus syndrome became transfusion independent. The defective 5q chromosome abnormality may be linked to other serious cancers, including leukemias and small cell lung cancer.

In another finding of the same study, all the patients with the 5q deletion who became transfusion independent also went into cytogenetic remission, meaning that the chromosome abnormality disappeared.

List, a professor of interdisciplinary oncology at the University of South Florida, initially developed the phase I clinical trial of Revlimid for treatment of MDS following his laboratory observations that the agent improved the growth of red blood cell precursors from MDS bone marrow. Celgene will submit the seminal findings of List's phase I trial - along with data from two recent confirmatory phase II clinical trials performed nationwide involving more than 350 patients with red blood cell transfusion-dependent MDS - to the U.S. Food and Drug Administration in a new drug application (NDA) for Revlimid as an innovative approach to treat the anemia of MDS patients with the 5q minus deletion.

In 2001, the National Cancer Institute awarded Moffitt the status of a Comprehensive Cancer Center in recognition of its excellence in re search and contributions to clinical trials, prevention and cancer control. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country's leading cancer centers, and is listed in the U.S. News & World Report as one of the top cancer hospitals in America. Moffitt's sole mission is to contribute to the prevention and cure of cancer.


'"/>

Source:University Of South Florida Health Sciences Center


Related biology news :

1. Protein That Promotes Survival Of Stem Cells Might Be Key To Poor Leukemia Prognosis
2. Genetically Modified Natural Killer Immune Cells Attack, Kill Leukemia Cells
3. Loosen up, DNA: Leukemia gene changes genetic packaging
4. Leukemia drug turns mini-molecules up, cancer genes down
5. Breakthrough Microarray-based Technology for the Study of Cancer
6. Breakthrough method in nanoparticle synthesis paves the way for new pharmaceutical and biomedical applications
7. Breakthrough isolating embryo-quality stem cells from blood
8. Breakthrough System for Understanding Ocean Plant Life Announced
9. Breakthrough: Scientists create worlds tiniest organic particles
10. Breakthrough in micro-device fabrication combines biology and synthetic chemistry
11. Sciences Breakthrough of the Year: Watching evolution in action
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/16/2017)... TEANECK, N.J. , May 16, 2017  Veratad ... leading provider of online age and identity verification solutions, ... the K(NO)W Identity Conference 2017, May 15 thru May ... Ronald Regan Building and International Trade Center. ... across the globe and in today,s quickly evolving digital ...
(Date:5/6/2017)... , May 5, 2017 ... just announced a new breakthrough in biometric authentication ... exploits quantum mechanical properties to perform biometric authentication. These ... smart semiconductor material created by Ram Group and ... finance, entertainment, transportation, supply chains and security. Ram ...
(Date:4/19/2017)... ALBANY, New York , April 19, 2017 /PRNewswire/ ... highly competitive, as its vendor landscape is marked by ... in the market is however held by five major ... and Safran. Together these companies accounted for nearly 61% ... majority of the leading companies in the global military ...
Breaking Biology News(10 mins):
(Date:5/22/2017)... ... May 22, 2017 , ... ... leaders of the Maryland Biohealth community in developing and issuing recommendations to grow ... U.S. BioHealth Innovation Hub by 2023. , The recommendations are ...
(Date:5/21/2017)... LOS ANGELES, CA (PRWEB) , ... May 19, ... ... at the annual meeting and educational conference of the American Association of Bioanalysts ... at the Galleria Hotel in Houston. The conference reinforces AAB’s commitment to excellence ...
(Date:5/19/2017)... ... May 19, 2017 , ... In response to the strong ... Biodex Medical Systems, Inc. announces the release of their Gait Trainer 3 with an ... with a biomedical system to aid in rehabilitating individuals with cerebral palsy, traumatic brain ...
(Date:5/18/2017)... ... May 18, 2017 , ... ... 28, 2017 at the Prince Of Wales Private Hospital. The procedure was performed ... C6-C7. The patient failed conservative treatments prior to undergoing surgery. , The AxioMed ...
Breaking Biology Technology: